EE115 Nash Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis from a Natural History Cohort in the US

E Tapper,J Fishman,A Mospan,B Munoz,P Newsome,R Loomba

doi:10.1016/j.jval.2023.03.419

EE115 Nash Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis from a Natural History Cohort in the US

E Tapper, J Fishman + Show 4 more

https://doi.org/10.1016/j.jval.2023.03.419

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Publication Date: Jun 1, 2023

Affiliation: University of Michigan–Ann Arbor, Madrigal Pharmaceuticals (United States), Target (United States), University of Birmingham, University of California, San Diego

#Fatty Liver Disease Activity Score #Nonalcoholic Fatty Liver Disease Activity + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Disease progression in nonalcoholic steatohepatitis (NASH) is assessed by progression of fibrosis (from F0 to F4 [most severe/cirrhosis]) and inflammation (using the nonalcoholic fatty liver disease activity score [NAS]), which are endpoints in clinical trials evaluating NASH therapeutics. In real-world patients, data supporting state transition probabilities in economic models are limited regarding fibrosis and lacking regarding NAS. This current analysis estimates NASH progression in a natural history cohort stratified by both baseline fibrosis stage and NAS.

Full Text